Last reviewed · How we verify
PD-1 and ACE2 Knockout T Cells — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PD-1 and ACE2 Knockout T Cells (PD-1 and ACE2 Knockout T Cells) — Mahmoud Ramadan mohamed Elkazzaz.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PD-1 and ACE2 Knockout T Cells TARGET | PD-1 and ACE2 Knockout T Cells | Mahmoud Ramadan mohamed Elkazzaz | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PD-1 and ACE2 Knockout T Cells CI watch — RSS
- PD-1 and ACE2 Knockout T Cells CI watch — Atom
- PD-1 and ACE2 Knockout T Cells CI watch — JSON
- PD-1 and ACE2 Knockout T Cells alone — RSS
Cite this brief
Drug Landscape (2026). PD-1 and ACE2 Knockout T Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/pd-1-and-ace2-knockout-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab